Trial Profile
Cilengitide in Subjects With Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). [The CORE Study]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs Cilengitide (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CORE
- Sponsors EMD Serono; Merck KGaA
- 07 Jun 2022 Results of an analysis comparing survival outcome using patient-level data from clinical studies: NCT00943826, NCT00813943, NCT00689221 and real-world data from an institutional dataset at a large academic center presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 19 Jan 2016 Pooled analysis of 4 studies (n=1869) including data from this study and 3 other trials (see CTP 700046838, 700038467, 700034867) were published in the Journal of Clinical Oncology.
- 24 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.